Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.005 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.1232 | 0.5 |
Schistosoma mansoni | lamin | 0.0027 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0027 | 0.3537 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.1232 | 0.5 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0016 | 0.0375 | 0.0375 |
Onchocerca volvulus | 0.0027 | 0.3537 | 0.5 | |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0.1232 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0.1232 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 0.3537 | 0.3537 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.1232 | 0.1657 |
Echinococcus multilocularis | lamin | 0.0027 | 0.3537 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.1232 | 0.5 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0016 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.1232 | 0.1232 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 0.3537 | 0.3537 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.1232 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0034 | 0.5545 | 0.5545 |
Schistosoma mansoni | lamin | 0.0027 | 0.3537 | 0.6116 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.1232 | 0.271 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.1232 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.1232 | 0.271 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.1232 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0027 | 0.3537 | 0.6116 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.1232 | 0.1657 |
Echinococcus multilocularis | musashi | 0.0027 | 0.3537 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.1232 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 0.3537 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0016 | 0.0375 | 0.0375 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0.1232 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 0.3537 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.5545 | 0.5545 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0375 | 0.0375 |
Onchocerca volvulus | 0.0027 | 0.3537 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0034 | 0.5545 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0.1232 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 0.3537 | 0.3537 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.1232 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.1232 | 0.1232 |
Echinococcus granulosus | lamin dm0 | 0.0027 | 0.3537 | 1 |
Brugia malayi | intermediate filament protein | 0.0027 | 0.3537 | 0.3537 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.1232 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.3397 | 0.3397 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.1232 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.1232 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.